ALX Oncology Holdings (ALXO) Earnings Date & Reports

Key Takeaways

• ALX Oncology Holdings (ALXO), a clinical-stage immuno-oncology company, is expected to report its third quarter 2026 results — for the period ended September 30, 2026 — in November 2026, though the company had not yet confirmed an exact date at the time of writing.
• Wall Street consensus points to a net loss of roughly $0.14 to $0.15 per share for the quarter, a sharp improvement from the $0.41 per-share loss reported in the same period a year earlier.
• As a development-stage biotech with no approved products, ALX Oncology reports no product revenue; investors will instead focus on operating expenses, cash burn, and clinical pipeline updates.
• The company's most recent quarter (Q2 2026) delivered a $0.13 per-share loss, beating consensus, continuing a trend of narrowing losses driven by cost discipline.
• Key catalysts to watch include updates on evorpacept, the lead CD47-blocking candidate, and ALX2004, an EGFR-targeted antibody-drug conjugate (ADC).
• Following a February 2026 registered offering of roughly $150 million, management has guided that its cash runway extends through the first half of 2028.
• For deeper coverage of this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for timely updates and analysis.
• Discover automated market insights and trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

ALX Oncology's quarterly earnings offer a window into how efficiently the clinical-stage company is managing capital while advancing its pipeline. With no marketed products, top-line revenue remains at zero, so investors parse expenses, cash position, and clinical milestones rather than sales. The third quarter comes on the heels of a $150 million capital raise that extended the company's runway into the first half of 2028, and follows encouraging data validating CD47 (a "don't eat me" signal used by cancer cells) as a predictive biomarker for its lead candidate, evorpacept. For a small-cap biotech trading near a multi-year low, this report serves as both a financial health check and a barometer of execution ahead of several data readouts expected over the next 12 to 18 months.

Earnings Expectations

Analysts expect ALX Oncology to report a net loss of approximately $0.14 to $0.15 per share for the third quarter of 2026, according to consensus estimates compiled by firms such as Zacks and MarketBeat. That compares with a $0.41 per-share loss in the third quarter of 2025, reflecting a meaningful year-over-year narrowing of losses as the company reduced its workforce, cut research and development spending, and prioritized its pipeline.

Revenue is expected to be $0, consistent with ALX Oncology's status as a clinical-stage developer with no approved products. In the prior quarter (Q2 2026), the company posted a $0.13 per-share loss that beat the consensus estimate of a $0.14 loss, and it has beaten EPS (earnings per share) estimates in several recent quarters. Beyond the headline numbers, investors will watch operating expenses, cash and investments, and any commentary on enrollment and timelines for the ASPEN-09 breast cancer trial and the Phase 1 study of ALX2004.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics, helping surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like ALXO, the screener offers a structured way to compare peers and monitor shifting market conditions. Explore the AI Screener to see how AI-driven filtering can support your research process.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious but stabilizing. Shares reached a multi-year low near $0.86 in mid-October 2026 before rebounding roughly 13% over the following 30 days, according to market data, as investors weighed the company's extended cash runway against ongoing clinical and execution risk. The consensus analyst rating on the stock is a Moderate Buy, with an average price target near $4.60, well above recent trading levels — reflecting a wide gap between current valuation and longer-term expectations.

Key risk factors ahead of the print include the company's continued cash burn, the early-stage nature of its pipeline, and binary clinical outcomes. Because ALX Oncology has no recurring revenue to cushion a disappointing update, the market's reaction will likely hinge less on the per-share loss itself and more on any shifts in guidance, trial timelines, or spending outlook.

Forward Outlook and Key Factors to Monitor

Looking beyond the third quarter, investors should track several clinical catalysts and financial signals. First, the ASPEN-09 breast cancer trial evaluating evorpacept is enrolling patients, with topline data anticipated around mid-2027. Commentary on enrollment pace and any biomarker-driven design updates will be closely watched, given the company's precision-oncology strategy centered on CD47 expression.

Second, the Phase 1 trial of ALX2004, an EGFR (epidermal growth factor receptor)-targeted antibody-drug conjugate, continues to escalate doses, with safety data from the dose-escalation phase expected in the second half of 2026. Any updates on dose-limiting toxicities or cohort progression could shape the asset's development path.

Financially, the key question is whether the company can sustain its reduced expense base while advancing both programs. Management has said existing cash, investments, and its term loan facility should fund operations through the first half of 2028, but investors will monitor quarterly cash burn to confirm that trajectory. Finally, Nasdaq listing compliance remains a background consideration, given the stock's low share price. As always with clinical-stage biotechs, results from ongoing trials — rather than near-term earnings figures — will ultimately drive the investment narrative.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations